Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

John F. DiPersio, MD, PhD, Robert H. Collins, Jr., MD, William Blum, MD, Marcel P Devetten, M.D., Patrick Stiff, MD, Laurence Elias, MD, Anita Reddy, Ph.D., Jennifer A. Smith, Ph.D., H. Jean Khoury, MD

Blood (2009) 114 (22): 633.

https://doi.org/10.1182/blood.V114.22.633.633

Published: 2009

Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD

Blood (2009) 114 (22): 636.

https://doi.org/10.1182/blood.V114.22.636.636

Published: 2009

Journal Articles

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Paul J. Martin, Barry E. Storer, Scott D. Rowley, Mary E. D. Flowers, Stephanie J. Lee, Paul A. Carpenter, John R. Wingard, Paul J. Shaughnessy, Marcel P. DeVetten, Madan Jagasia, Joseph W. Fay, Koen van Besien, Vikas Gupta, Carrie Kitko, Laura J. Johnston, Richard T. Maziarz, Mukta Arora, Pamala A. Jacobson, Daniel Weisdorf

Blood (2009) 113 (21): 5074–5082.

https://doi.org/10.1182/blood-2009-02-202937

Published: 2009

Includes: Supplemental data

Journal Articles

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Jorge E. Cortes, Darejan Ghirdaladze, James M. Foran, Marcel P. DeVetten, Mamia Zodelava, Mark J. Levis, Norman M. Padre, James Joyce, Patrick P. Zarrinkar, Robert Corringham

Blood (2008) 112 (11): 767.

https://doi.org/10.1182/blood.V112.11.767.767

Published: 2008

Journal Articles

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Robert E Gallagher, MD, Esther L Schachter- Tokarz, BA, Lawrence E. Morris, Tianna Dauses, BSN, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Robert L. Redner, MD, Mikkael A. Sekeres, MD, MS, Ibitayo Owoeye, MD, Steven D. Gore, MD

Blood (2008) 112 (11): 1502.

https://doi.org/10.1182/blood.V112.11.1502.1502

Published: 2008

Journal Articles

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Steven D. Gore, MD, Lawrence Morris, MD, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Mikkael A. Sekeres, MD, MS, Robert J. Arceci, MD, PhD, Robert L. Redner, MD, Tianna Dauses, BSN, Esther L Schachter-Tokarz, Ibitayo Owoeye, MD, Robert E. Gallagher, MD

Blood (2008) 112 (11): 1932.

https://doi.org/10.1182/blood.V112.11.1932.1932

Published: 2008

Journal Articles

Outcomes of Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

John D. Dickinson, MD, PhD, Fausto Loberiza, MD, Victoria Whalen, Philip J. Bierman, MD, Julie M. Vose, MD, Marcel P. Devetten, MD, Lori J. Maness, MD, James O. Armitage, MD, Greg Bociek, MD

Blood (2007) 110 (11): 3045.

https://doi.org/10.1182/blood.V110.11.3045.3045

Published: 2007

Journal Articles

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

Jorge Cortes, James M. Foran, Marcel P. Devetten, Francis J. Giles, Joyce James, Patrick P. Zarrinkar, Michael H. Silverman, Kerry A. Kelly, Norman M. Padre, Shripad Bhagwat, Wendell Wierenga

Blood (2007) 110 (11): 1597.

https://doi.org/10.1182/blood.V110.11.1597.1597

Published: 2007

Journal Articles

Mechanism of Alemtuzumab Depletion of T Cells in Stem Cell Products.

Dumrul Gulen, PhD, Robert G. Bociek, MD, Ugur Coskun, MD, Marcel P. Devetten, MD, James E. Talmadge, PhD

Blood (2006) 108 (11): 5176.

https://doi.org/10.1182/blood.V108.11.5176.5176

Published: 2006

Journal Articles

Strategy for Managing Patients with Prior Invasive Aspergillosis through Allogeneic Transplant.

Amit W. Panwalkar, MD, Marcel P. DeVetten, MD, R. Gregory Bociek, MD, Alison G. Freifeld, MD

Blood (2006) 108 (11): 5318.

https://doi.org/10.1182/blood.V108.11.5318.5318

Published: 2006

Journal Articles

Unrelated Donor Nonmyeloablative/Reduced Intensity (NST/RIC) Hematopoietic Stem Cell Transplantation (HCT) for Patients with Relapsed and Refractory Hodgkin’s Lymphoma (HL).

Marcel P. Devetten, MD, Parameswaran Hari, MD, Jeanette Carerras, MPH, Brent R. Logan, PhD, Koen van Besien, MD, Julie M. Vose, MD, Hillard M. Lazarus, MD, Paolo Anderlini, MD

Blood (2006) 108 (11): 601.

https://doi.org/10.1182/blood.V108.11.601.601

Published: 2006

Journal Articles

Differential Expression of Hem1 and CTLA-4 in B-CLL Patients with High and Low CD38 Expression.

Avadhut D. Joshi, B.Pharm, John D. Dickinson, PhD, James C. Lynch, PhD, Philip J. Bierman, MD, Gregory R. Bociek, MD, Marcel P. Devetten, MD, James O. Armitage, MD, Shantaram S. Joshi, PhD

Blood (2005) 106 (11): 2103.

https://doi.org/10.1182/blood.V106.11.2103.2103

Published: 2005

Journal Articles

Outcomes Following Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with or without Advanced Care Planning.

Apar Kishor Ganti, MD, Stephanie J. Lee, MD, MPH, James O. Armitage, MD, Philip J. Bierman, MD, Gregory Bociek, MD, Marcel P. Devetten, MD, Lori J. Maness, MD, Elizabeth C. Reed, MD, Julie M. Vose, MD, Fausto Loberiza, MD, MS

Blood (2005) 106 (11): 2025.

https://doi.org/10.1182/blood.V106.11.2025.2025

Published: 2005

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) for Hematologic Malignancies (HM) Using Pentostatin/Low-Dose Total Body Irradiation (TBI).

R. Gregory Bociek, MD, MSc, James E. Talmadge, PhD, James C. Lynch, PhD, Charles A. Enke, MD, Charles A. Kuszynski, PhD, Philip J. Bierman, MD, Julie M. Vose, MD, James O. Armitage, MD, Marcel P. Devetten, MD, Lori J. Maness, MD, Timothy R. McGuire, PhD, James L. Wisecarver, MD, Shantaram S. Joshi, PhD, Zivko S. Pavletic, MD

Blood (2005) 106 (11): 3671.

https://doi.org/10.1182/blood.V106.11.3671.3671

Published: 2005

Journal Articles

Low Dose Alemtuzumab (Campath 1H) Prior to Allogeneic Stem Cell Transplantation Is Associated with Low Incidence of Acute and Chronic GVHD but Protracted Immune Recovery.

Marcel P. Devetten, MD, Fausto Loberiza, MD, Robin Weisenborn, MT CCRC, Pam Bunner, MT CCRC, Jamie Brewer, Solveig Ericson, MD

Blood (2005) 106 (11): 5376.

https://doi.org/10.1182/blood.V106.11.5376.5376

Published: 2005

Journal Articles

Molecular Chaperone GRP94 Binds to the Fanconi Anemia Group C Protein and Regulates Its Intracellular Expression

Taizo Hoshino, Jianxiang Wang, Marcel P. Devetten, Nobuhisa Iwata, Sachiko Kajigaya, Robert J. Wise, Johnson M. Liu, Hagop Youssoufian

Blood (1998) 91 (11): 4379–4386.

https://doi.org/10.1182/blood.V91.11.4379

Published: 1998

NARROW

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Outcomes of Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

Mechanism of Alemtuzumab Depletion of T Cells in Stem Cell Products.

Strategy for Managing Patients with Prior Invasive Aspergillosis through Allogeneic Transplant.

Unrelated Donor Nonmyeloablative/Reduced Intensity (NST/RIC) Hematopoietic Stem Cell Transplantation (HCT) for Patients with Relapsed and Refractory Hodgkin’s Lymphoma (HL).

Differential Expression of Hem1 and CTLA-4 in B-CLL Patients with High and Low CD38 Expression.

Outcomes Following Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with or without Advanced Care Planning.

Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) for Hematologic Malignancies (HM) Using Pentostatin/Low-Dose Total Body Irradiation (TBI).

Low Dose Alemtuzumab (Campath 1H) Prior to Allogeneic Stem Cell Transplantation Is Associated with Low Incidence of Acute and Chronic GVHD but Protracted Immune Recovery.

Molecular Chaperone GRP94 Binds to the Fanconi Anemia Group C Protein and Regulates Its Intracellular Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only